Gilead Sciences, Inc. has announced that Trodelvy (sacituzumab govitecan-hziy) has received Breakthrough Therapy Designation ...

Researchers have used a chemical compound to light up treatment-resistant cancers on imaging scans, in a breakthrough that ...

Researchers at the Icahn School of Medicine at Mount Sinai have identified the mechanism of action of a treatment for ...

Gilead Sciences GILD announced that its first-in-class Trop-2-directed antibody-drug conjugate, Trodelvy (sacituzumab ...

Preliminary clinical data in post-anti-PD-1 NSCLC patients demonstrated a 27% ORR and 73% DCR in monotherapy trialMonotherapy activity with ...

Teos Therapeutics has potential lung cancer treatment despite issues and strong financial position. Read here to know why we ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit looks back on the progress made toward better understanding and ...

Jazz Pharmaceuticals announced that the FDA has approved ZIIHERA® (zanidatamab-hrii) on an accelerated basis for the treatment ...

The FDA granted breakthrough therapy designation to sacituzumab govitecan for patients with ES-SCLC progressing on platinum ...

Researchers have used a chemical compound to light up treatment-resistant cancers on imaging scans, in a breakthrough that ...

Presurgical camrelizumab plus chemotherapy significantly improved responses versus chemotherapy alone in early or locally ...